UK markets closed

Nexstim Plc (NXTMS.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
47.30-1.70 (-3.47%)
At close: 5:11PM CEST
Full screen
Previous close49.00
Open48.00
Bid46.80 x 0
Ask47.90 x 0
Day's range46.70 - 48.00
52-week range25.32 - 98.27
Volume796
Avg. volume2,870
Market cap316.279M
Beta (5Y monthly)2.25
PE ratio (TTM)N/A
EPS (TTM)-0.79
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Nexstim Receives System Orders from Existing Hospital Customers in Finland

    Press release, Helsinki, 15 September 2021 at 9 AM (EEST) Nexstim Receives System Orders from Existing Hospital Customers in Finland Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having received two new system orders from existing hospital customers in Finland. One of the hospitals has ordered an NBT® system to be used for treatment of major depression and chronic neuropathic pain. The other order is for an NBS system that will be used for both diagnostics and therapeutic

  • Globe Newswire

    Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

    Company Announcement, Inside information, Helsinki, 23 August 2021 at 10:45 AM (EEST) Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the continuation of the pilot study on the use of accelerated iTBS protocol in treatment of severe depression with Nexstim NBT® System at Kuopio University Hospital. The start of the pilot study was first announced on 22 September 202

  • Globe Newswire

    Nexstim Reaches 208 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

    Press release, Helsinki, 20 August 2021 at 9 AM (EEST) Nexstim Reaches 208 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") reports clinical outcomes of the 208 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD). Nexstim NBT® system is indicated for the treatment of MDD in adult patients wh